These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 30091530)

  • 1. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.
    Wu JC; Jiang HM; Yang XH; Zheng HC
    Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.
    Yang XF; Zhao ZJ; Liu JJ; Yang XH; Gao Y; Zhao S; Shi S; Huang KQ; Zheng HC
    Oncotarget; 2017 Jan; 8(2):3156-3169. PubMed ID: 27911270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
    Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
    PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The down-regulated ING5 expression in lung cancer: a potential target of gene therapy.
    Zhao S; Yang XF; Shen DF; Gao Y; Shi S; Wu JC; Liu HX; Sun HZ; Su RJ; Zheng HC
    Oncotarget; 2016 Aug; 7(34):54596-54615. PubMed ID: 27409347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells.
    Lu H; Yang XF; Tian XQ; Tang SL; Li LQ; Zhao S; Zheng HC
    Oncotarget; 2016 Aug; 7(35):56508-56525. PubMed ID: 27447743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ING5 suppresses proliferation, apoptosis, migration and invasion, and induces autophagy and differentiation of gastric cancer cells: a good marker for carcinogenesis and subsequent progression.
    Gou WF; Shen DF; Yang XF; Zhao S; Liu YP; Sun HZ; Su RJ; Luo JS; Zheng HC
    Oncotarget; 2015 Aug; 6(23):19552-79. PubMed ID: 25980581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of retinoic acid and histone deacetylase inhibitors on human neuroblastoma SH-SY5Y cells.
    De los Santos M; Zambrano A; Aranda A
    Mol Cancer Ther; 2007 Apr; 6(4):1425-32. PubMed ID: 17431121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
    Richon VM; Sandhoff TW; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
    Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
    Gillenwater AM; Zhong M; Lotan R
    Mol Cancer Ther; 2007 Nov; 6(11):2967-75. PubMed ID: 18025281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
    Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
    PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects.
    Carlisi D; Vassallo B; Lauricella M; Emanuele S; D'Anneo A; Di Leonardo E; Di Fazio P; Vento R; Tesoriere G
    Int J Oncol; 2008 Jan; 32(1):177-84. PubMed ID: 18097557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model.
    Feng D; Wu J; Tian Y; Zhou H; Zhou Y; Hu W; Zhao W; Wei H; Ling B; Ma C
    PLoS One; 2013; 8(11):e80657. PubMed ID: 24260446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
    Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
    Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X; Han H; Zou D; Zhou J; Zhou W
    Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ING5 is a Tip60 cofactor that acetylates p53 in response to DNA damage.
    Liu N; Wang J; Wang J; Wang R; Liu Z; Yu Y; Lu H
    Cancer Res; 2013 Jun; 73(12):3749-60. PubMed ID: 23576563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest.
    Yang H; Xu W; Li Y; Lan P; Zhang J; Zhang Y; Zhang C
    Anticancer Drugs; 2014 Aug; 25(7):767-77. PubMed ID: 24686006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.
    Chen WT; Yang YJ; Zhang ZD; An Q; Li N; Liu W; Yang B
    J Ovarian Res; 2017 Jan; 10(1):1. PubMed ID: 28086946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.